1. Minimally invasive pancreatic surgery: the new frontier?
- Author
-
Saleh Baghdadi and Basil J. Ammori
- Subjects
medicine.medical_specialty ,Percutaneous ,medicine.medical_treatment ,Enucleation ,Splenectomy ,Malignancy ,Pancreatic surgery ,Pancreaticoduodenectomy ,Pancreatectomy ,Postoperative Complications ,Blood loss ,Laparotomy ,medicine ,Humans ,Pancreas ,business.industry ,General surgery ,Gastroenterology ,General Medicine ,medicine.disease ,Surgery ,Pancreatic Neoplasms ,Treatment Outcome ,Laparoscopy ,Distal pancreatectomy ,business - Abstract
Recent advances in minimally invasive pancreatic surgery encompass laparoscopic, retroperitoneoscopic, endoscopic, thoracoscopic, and percutaneous approaches. Applications of endoscopic pancreatic surgery include laparoscopic resection, necrosectomy, drainage of pseudocysts, gastric and biliary bypass, and thoracoscopic splanchnotomy. This review provides an update on laparoscopic pancreatic resections. Over 400 cases of laparoscopic distal pancreatectomy (LDP) and enucleation (LEn) have been reported in the English literature, largely for benign disease. LDP and LEn have been associated with reductions in blood loss, morbidity, and hospital stay and a greater rate of splenic preservation compared with open surgery. Laparoscopic ultrasound is essential for intraoperative localization of insulinomas because failure of localization is the most common cause for conversion to laparotomy. The role of LDP with en bloc splenectomy and laparoscopic pancreaticoduodenectomy (LPD) for malignancy remains controversial. The majority of LPDs have been performed for malignancy. The short-term results of the limited world experience of 34 reported LPDs appear favorable.
- Published
- 2006